{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:02:40Z","timestamp":1785816160260,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clml.2020.05.019","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T20:36:36Z","timestamp":1590698196000},"page":"697-703.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera"],"prefix":"10.1016","volume":"20","author":[{"given":"Alexander","family":"Coltoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-3485","authenticated-orcid":false,"given":"Jessica","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Siwoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott F.","family":"Winton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7647-8922","authenticated-orcid":false,"given":"Swati","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-4709","authenticated-orcid":false,"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.05.019_bib1","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","article-title":"Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms","volume":"54","author":"Abelsson","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.019_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.019_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","article-title":"Complications and causes of death in polycythaemia vera","volume":"172","author":"Chievitz","year":"1962","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.clml.2020.05.019_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ajh.2830340108","article-title":"Leukemic transformation in polycythemia vera: analysis of risk factors","volume":"34","author":"Nand","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib5","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.019_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2020.05.019_bib7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.019_bib8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.clml.2020.05.019_bib9","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1002\/ajh.25017","article-title":"JAK2 exon 12 mutated polycythemia vera: the Mayo Clinic-University of Florence experience with 33 consecutive cases and comparison with JAK2 V617F mutated disease","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.019_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.019_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","article-title":"Current and future treatment options for polycythemia vera","volume":"94","author":"Griesshammer","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.05.019_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-99-111946","article-title":"Interim analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia","volume":"132","author":"Mascarenhas","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.019_bib16","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib17","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.019_bib18","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.05.019_bib19","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.019_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.019_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.019_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.05.019_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.05.019_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.clml.2020.05.019_bib25","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1080\/10428194.2019.1636985","volume":"60","author":"Holtz","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.019_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"176","author":"Mesa","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.019_bib27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.05.019_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12185-017-2333-y","article-title":"Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly","volume":"107","author":"Kirito","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00277-017-3225-1","article-title":"Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies","volume":"97","author":"Kiladjian","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.05.019_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/2040620717693972","article-title":"Experience with ruxolitinib in the treatment of polycythaemia vera","volume":"8","author":"Alimam","year":"2017","journal-title":"Ther Adv Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:30Z","timestamp":1761870990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2152265020302652"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}